A switch in hepatic cortisol metabolism across the spectrum of non alcoholic fatty liver disease

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Ahmed, Adeeba ^a   Rabbitt, Elizabeth ^a   Brady, Theresa ^b   Brown, Claire ^b   Guest, Peter ^b   Bujalska, Iwona J ^a   Doig, Craig ^a   Newsome, Philip N ^b   Hubscher, Stefan ^b   Elias, Elwyn ^b   Adams, David H ^b   Tomlinson, Jeremy W ^a   Stewart, Paul M ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; CD68 ANTIGEN; CORTISONE ACETATE; DEXAMETHASONE; HYDROCORTISONE; MESSENGER RNA; STEROID 5ALPHA REDUCTASE;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; GAS CHROMATOGRAPHY; HEPATITIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYDROCORTISONE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER CELL; LIVER CIRRHOSIS; LIVER CLEARANCE; LIVER METABOLISM; LIVER PROTECTION; MACROPHAGE; METABOLITE; NONALCOHOLIC FATTY LIVER; OBESITY; PROTEIN EXPRESSION; STEATOSIS; STEROID METABOLISM; STEROIDOGENESIS; URINALYSIS; BIOLOGICAL MODEL; CASE CONTROL STUDY; DISEASE COURSE; ENZYMOLOGY; FATTY LIVER; GENE EXPRESSION REGULATION; GENETICS; LIVER; METABOLISM; MIDDLE AGED; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; URINE;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ADULT; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FATTY LIVER; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; HYDROCORTISONE; LIVER; MIDDLE AGED; MODELS, BIOLOGICAL; OBESITY; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84857403547     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029531     Document Type: Article

References (44)

1. de Alwis NM, Day CP, (2008) Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 48 (Suppl 1): S104-S112.
2. Rockall AG, Sohaib SA, Evans D, Kaltsas G, Isidori AM, et al. (2003) Hepatic steatosis in Cushing's syndrome: a radiological assessment using computed tomography. Eur J Endocrinol 149: 543-548.
3. Dourakis SP, Sevastianos VA, Kaliopi P, (2002) Acute severe steatohepatitis related to prednisolone therapy. Am J Gastroenterol 97: 1074-1075.
4. Nanki T, Koike R, Miyasaka N, (1999) Subacute severe steatohepatitis during prednisolone therapy for systemic lupus erythematosis. Am J Gastroenterol 94: 3379.
5. Hellerstein MK, (1999) De novo lipogenesis in humans: metabolic and regulatory aspects. Eur J Clin Nutr 53 (Suppl 1): S53-S65.
6. Norrheim L, Sorensen H, Gautvik K, Bremer J, Spydevold O, (1990) Synergistic actions of tetradecylthioacetic acid (TTA) and dexamethasone on induction of the peroxisomal beta-oxidation and on growth inhibition of Morris hepatoma cells. Both effects are counteracted by insulin. Biochim Biophys Acta 1051: 319-323.
7. Dolinsky VW, Douglas DN, Lehner R, Vance DE, (2004) Regulation of the enzymes of hepatic microsomal triacylglycerol lipolysis and re-esterification by the glucocorticoid dexamethasone. Biochem J 378: 967-974.
8. Baxter JD, Forsham PH, (1972) Tissue effects of glucocorticoids. Am J Med 53: 573-589.
9. Stewart PM, Boulton A, Kumar S, Clark PM, Shackleton CH, (1999) Cortisol metabolism in human obesity: impaired cortisone→cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab 84: 1022-1027.
10. Bujalska IJ, Gathercole LL, Tomlinson JW, Darimont C, Ermolieff J, et al. (2008) A novel selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitor prevents human adipogenesis. J Endocrinol 197: 297-307.
11. Rosenstock J, Banarer S, Fonseca VA, Inzucchi SE, Sun W, et al. (2010) The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care 33: 1516-1522.
12. Tomlinson JW, Stewart PM, (2005) Mechanisms of disease: Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome. Nat Clin Pract Endocrinol Metab 1: 92-99.
13. Konopelska S, Kienitz T, Hughes B, Pirlich M, Bauditz J, et al. (2009) Hepatic 11beta-HSD1 mRNA expression in fatty liver and nonalcoholic steatohepatitis. Clin Endocrinol (Oxf) 70: 554-560.
14. Targher G, Bertolini L, Rodella S, Zoppini G, Zenari L, et al. (2006) Associations between liver histology and cortisol secretion in subjects with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 64: 337-341.
15. Westerbacka J, Yki-Jarvinen H, Vehkavaara S, Hakkinen AM, Andrew R, et al. (2003) Body fat distribution and cortisol metabolism in healthy men: enhanced 5beta-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver. J Clin Endocrinol Metab 88: 4924-4931.
16. Borkan GA, Gerzof SG, Robbins AH, Hults DE, Silbert CK, et al. (1982) Assessment of abdominal fat content by computed tomography. Am J Clin Nutr 36: 172-177.
17. Stewart PM, Wallace AM, Atherden SM, Shearing CH, Edwards CR, (1990) Mineralocorticoid activity of carbenoxolone: contrasting effects of carbenoxolone and liquorice on 11 beta-hydroxysteroid dehydrogenase activity in man. Clin Sci (Lond) 78: 49-54.
18. Palermo M, Shackleton CH, Mantero F, Stewart PM, (1996) Urinary free cortisone and the assessment of 11 beta-hydroxysteroid dehydrogenase activity in man. Clin Endocrinol (Oxf) 45: 605-611.
19. Shackleton CH, (1993) Mass spectrometry in the diagnosis of steroid-related disorders and in hypertension research. J Steroid Biochem Mol Biol 45: 127-140.
20. Ricketts ML, Verhaeg JM, Bujalska I, Howie AJ, Rainey WE, et al. (1998) Immunohistochemical localization of type 1 11beta-hydroxysteroid dehydrogenase in human tissues. J Clin Endocrinol Metab 83: 1325-1335.
21. Lavery GG, Walker EA, Draper N, Jeyasuria P, Marcos J, et al. (2006) Hexose-6-phosphate dehydrogenase knock-out mice lack 11 beta-hydroxysteroid dehydrogenase type 1-mediated glucocorticoid generation. J Biol Chem 281: 6546-6551.
22. Burchell A, Hume R, Burchell B, (1988) A new microtechnique for the analysis of the human hepatic microsomal glucose-6-phosphatase system. Clin Chim Acta 173: 183-191.
23. Laemmli UK, (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685.
24. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, et al. (2001) A transgenic model of visceral obesity and the metabolic syndrome. Science 294: 2166-2170.
25. Morton NM, Holmes MC, Fievet C, Staels B, Tailleux A, et al. (2001) Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem 276: 41293-41300.
26. Paterson JM, Morton NM, Fievet C, Kenyon CJ, Holmes MC, et al. (2004) Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci U S A 101: 7088-7093.
27. Berthiaume M, Laplante M, Festuccia WT, Berger JP, Thieringer R, et al. (2009) Preliminary report: pharmacologic 11beta-hydroxysteroid dehydrogenase type 1 inhibition increases hepatic fat oxidation in vivo and expression of related genes in rats fed an obesogenic diet. Metabolism S0026-0495(09)00292-3.
28. Tomlinson JW, Finney J, Hughes BA, Hughes SV, Stewart PM, (2008) Reduced glucocorticoid production rate, decreased 5alpha-reductase activity, and adipose tissue insulin sensitization after weight loss. Diabetes 57: 1536-1543.
29. Vassiliadi DA, Barber TM, Hughes BA, McCarthy MI, Wass JA, et al. (2009) Increased 5{alpha}-reductase activity and adrenocortical drive in women with polycystic ovary syndrome. J Clin Endocrinol Metab 94 (9): 3558-3566.
30. Antakly T, Eisen HJ, (1984) Immunocytochemical localization of glucocorticoid receptor in target cells. Endocrinology 115: 1984-1989.
31. Gilmour JS, Coutinho AE, Cailhier JF, Man TY, Clay M, et al. (2006) Local amplification of glucocorticoids by 11 beta-hydroxysteroid dehydrogenase type 1 promotes macrophage phagocytosis of apoptotic leukocytes. J Immunol 176: 7605-7611.
32. Ishii T, Masuzaki H, Tanaka T, Arai N, Yasue S, et al. (2007) Augmentation of 11beta-hydroxysteroid dehydrogenase type 1 in LPS-activated J774.1 macrophages-role of 11beta-HSD1 in pro-inflammatory properties in macrophages. FEBS Lett 581: 349-354.
33. Heydtmann M, (2009) Macrophages in hepatitis B and hepatitis C virus infections. J Virol 83: 2796-2802.
34. Hardy R, Rabbitt EH, Filer A, Emery P, Hewison M, et al. (2008) Local and systemic glucocorticoid metabolism in inflammatory arthritis. Ann Rheum Dis 67: 1204-1210.
35. Zbankova S, Bryndova J, Leden P, Kment M, Svec A, et al. (2007) 11beta-hydroxysteroid dehydrogenase 1 and 2 expression in colon from patients with ulcerative colitis. J Gastroenterol Hepatol 22: 1019-1023.
36. Dover AR, Hadoke PW, Macdonald LJ, Miller E, Newby DE, et al. (2007) Intravascular glucocorticoid metabolism during inflammation and injury in mice. Endocrinology 148: 166-172.
37. Rae MT, Niven D, Ross A, Forster T, Lathe R, et al. (2004) Steroid signalling in human ovarian surface epithelial cells: the response to interleukin-1alpha determined by microarray analysis. J Endocrinol 183: 19-28.
38. Cooper MS, Bujalska I, Rabbitt E, Walker EA, Bland R, et al. (2001) Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation. J Bone Miner Res 16: 1037-1044.
39. Chapman KE, Coutinho AE, Gray M, Gilmour JS, Savill JS, et al. (2009) The role and regulation of 11beta-hydroxysteroid dehydrogenase type 1 in the inflammatory response. Mol Cell Endocrinol 301: 123-131.
40. Williams LJ, Lyons V, MacLeod I, Rajan V, Darlington GJ, et al. (2000) C/EBP regulates hepatic transcription of 11beta-hydroxysteroid dehydrogenase type 1. A novel mechanism for cross-talk between the C/EBP and glucocorticoid signaling pathways. J Biol Chem 275: 30232-30239.
41. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, et al. (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112: 1796-1808.
42. Feldstein AE, Werneburg NW, Canbay A, Guicciardi ME, Bronk SF, et al. (2004) Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 40: 185-194.
43. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, et al. (2005) Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 11: 183-190.
44. Ahmed A, Saksena S, Sherlock M, Olliff SP, Elias E, et al. (2008) Induction of hepatic 11beta-hydroxysteroid dehydrogenase type 1 in patients with alcoholic liver disease. Clin Endocrinol (Oxf) 68: 898-903.